They Call It “Informed Consent.” It Isn’t.

The speaker argues that the informed consent form is dishonest because it relies on a sanitized subset of evidence. By filing FOIA requests, Irving Kirsch demonstrated that 31% of antidepressant trials were never published and 15% were spun to look positive. If patients demanded to see all the data — including the unpublished trials and the raw numbers from the published ones — they would realize that the drug's added benefit over placebo is a mere 1.8 points on a 0–51 scale, less than the effect of a good night's sleep. This protocol thus becomes a gatekeeping step: refuse to sign until you have the full evidence. The speaker does not provide a practical method for obtaining this data but uses the demand as a rhetorical device to expose the consent process as a sham.

The speaker notes that if patients truly knew that antidepressants provide only a tiny additional benefit over placebo and come with a package of severe side effects, they would likely gravitate toward lower-risk options. He lists exercise, St. John's Wort, omega-3 fatty acids, and working on sleep as examples of 'anything that creates a better benefit to harm ratio.' These approaches address the root causes or leverage the body's own healing mechanisms without causing the neurochemical blunting or withdrawal syndrome associated with SSRIs. He does not provide dosing or duration but emphasizes that the placebo effect — the mind's ability to heal the body — is the real heavy lifter and should be nurtured through belief and lifestyle changes rather than dismissed.

The speaker argues that the foundation of antidepressant prescribing is built on cherry-picked data. Kirsch's FOIA requests unearthed raw trial data that drug companies had hidden. Out of 74 trials conducted, 31% were never published because the results were unfavorable. An additional 15% were rewritten to spin negative outcomes into positive ones. This manipulation inflated the perceived benefit by 32%. Because physicians only see the published studies, they cannot give patients an honest assessment of a drug's true efficacy. The speaker contends that both doctors and patients are therefore misinformed, rendering the informed consent process fraudulent. He proposes that all raw data and every trial result should be publicly available so patients can make genuinely informed decisions.

The speaker points out that the Hamilton Depression Scale ranges from 0 to 51 and is scored by the doctor observing the patient, not by the patient's self-report or any objective biomarker. This means that if a person looks depressed, the doctor can check off items accordingly. The scale was originally designed by Max Hamilton to assess severity in already-diagnosed patients, not as a diagnostic tool, yet it has become the standard for measuring depression in clinical trials. The speaker uses this to argue that the entire evidentiary base for antidepressants is built on subjective judgment, not hard science. This subjectivity makes it easier for drug companies to spin minimal differences into 'significant' results, especially when they can exclude unfavorable trials.

The speaker visualizes the 0–51 scale as 51 feet across a whiteboard. He explains that when you look at the raw data across all 74 trials, the placebo reduced depression scores by 9.6 points, while the drug only brought an additional 1.8-point reduction. That means 82% of the total improvement came from the placebo effect. He contrasts this with the UK's National Institute of Health standard, which requires at least a 3-point difference for clinical significance — a threshold the drug fails to meet. Only in the United States is the tiny 1.8-point bump accepted as enough to support a $19 billion industry. The speaker emphasizes that a simple good night's sleep can reduce depression by 6 points, more than three times the drug's added benefit. He argues that the focus should be on investigating the heavy lifter — the placebo effect — and lifestyle factors, not on drugs with such a poor benefit-to-harm ratio.

The speaker describes emotional blunting as 'probably the worst side effect of all.' It occurs in 40–60% of patients and involves a state where you cannot feel enjoyment, pleasure, or any emotion — you become numb. While you may be less sad, you also lose the capacity for positive feelings. Despite its prevalence and severity, the informed consent form makes no mention of it. The speaker sees this as a critical omission that undermines the validity of the consent: a patient cannot knowingly accept a treatment if a major risk is concealed. He ties this to the broader pattern of minimizing harms while exaggerating benefits.

The speaker explains that discontinuing antidepressants is not a simple matter. Patients often need to taper off 'very slowly, sometimes over the course of months or even years.' Some incur expenses of $30,000 a year just to get off a drug they are stuck on. Additional withdrawal symptoms can include insomnia, nausea, anxiety, and even depression — the very thing the drug was supposed to treat. The combination of a hidden side effect (emotional blunting), a difficult exit, and high cost makes the risk-to-benefit ratio heavily skewed. The speaker maintains that if patients knew in advance they might not be able to stop the medication without major disruption, they would likely opt for lifestyle-based interventions first.